GLAXF GSK PLC
- 20.800
- -0.500-2.35%
GSK PLC News
GSK Raises Profit Guidance as Vaccine Demand Grows
GSK Q1 Core Earnings, Revenue Advance; 2024 Outlook Lifted -- Shares Up Pre-Bell
GSK (GSK) reported Q1 core earnings Wednesday of 0.431 British pounds ($0.54) per share, up from 0.37 pounds a year earlier. Analysts polled by Capital IQ expected 0.37 pounds. Turnover for the quarte
Trending: GSK Lifts Profit Guidance On Earnings Beat
0922 GMT - GSK is among the most mentioned companies across news items over the past twelve hours after it lifted its profit guidance for the year, according to Factiva data. The British pharmaceutica
Trending Tickers: Amazon, AMD, GSK and Aston Martin
GSK Results Are Solid Despite Lower Expected Sales, Arexvy Miss -- Market Talk
0819 GMT - GSK's core earnings per share beat and full-year guidance lift outweigh expected lower sales in the second half and a sales miss for its respiratory syncytial virus vaccine Arexvy, Citi ana
GSK Raises Outlook for 2024 as Higher First-quarter Turnover Boosts Confidence
Thanks to turnover growth in the first quarter led by business momentum across all product areas, GSK (GSK.L) is now more bullish regarding its growth prospects for 2024, according to its Wednesday re
GSK Lifts Guidance After Turnover Beats Expectations
By Helena Smolak GSK lifted its full-year guidance after first-quarter turnover rose and beating expectations, helped by higher sales in its vaccines and specialty medicines segment. The British pha
GSK Posts Lower Q1 Attributable Profit; Turnover Up
GSK (GSK.L) said Wednesday that profit for the first quarter decreased while turnover increased year over year. Profit attributable to shareholders for the three months ended March 31 was 1.05 billion
GSK PLC Sees 2024 Turnover Growth in the Upper Range of 5%-7%
GSK PLC Sees 2024 Turnover Growth in the Upper Range of 5%-7%
GSK PLC Raises 2024 View
GSK PLC Raises 2024 View
GSK PLC Declares Dividend of 15p Vs 14p
GSK PLC Declares Dividend of 15p Vs 14p
GSK PLC 1Q Pretax Pft GBP1.36B
GSK PLC 1Q Pretax Pft GBP1.36B
GSK PLC 1Q Oper Pft GBP1.49B
GSK PLC 1Q Oper Pft GBP1.49B
GSK's Application for Jemperli's Expanded Indication Accepted by FDA for Priority Review
GSK (GSK) said Wednesday that the US Food and Drug Administration granted priority review to its supplemental Biologics License Application for Jemperli in combination with chemotherapy to expand trea
GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix
GSK (GSK) on Wednesday reported positive results from phase 3 trials for gepotidacin, an oral antibiotic to treat urogenital gonorrhea, and Shingrix, its shingles vaccine. The drug maker said gepotida
GSK's Uncomplicated Urogenital Gonorrhea Treatment Meets Primary Endpoint in Late-stage Trial
British drugmaker GSK (GSK.L) on Wednesday said a phase 3 trial of its gepotidacin drug for treating uncomplicated urogenital gonorrhea in adolescents and adults met its primary endpoint. The oral ant
GSK Says US FDA Accepts Meningococcal Vaccine Candidate for Regulatory Review
GSK (GSK) said in a regulatory filing Tuesday that the US Food and Drug Administration has accepted for review the company's biologics license application for its meningococcal ABCWY vaccine candidate
GSK PLC Sponsored ADR (GSK) Is Attracting Investor Attention: Here Is What You Should Know
Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
Analysis
Price Target
No Data
